For Biosimilars Under Medicare, It Is Just The Beginning

Law360, New York (April 16, 2015, 5:01 PM ET) -- On March 30, 2015, in the wake of the first biosimilar product licensed by the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services issued several guidance documents addressing the treatment of biosimilar products under Medicare Part B, Medicare Part D and the Medicaid Drug Rebate Program.



Generally, because biosimilar products do not meet the definitions of “generic” or “multiple source” drugs under either the Medicare or Medicaid programs, in part because biosimilars are approved via a biological license application, CMS will treat...

To view the full article, register now.